Literature DB >> 3152971

White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate.

K Schmiegelow1, M K Pulczynska, M Seip.   

Abstract

In a retrospective study of 84 children with standard-risk acute lymphoblastic leukemia diagnosed in 1981-1986, mean white cell count (mWBC) during maintenance chemotherapy (MT) was found to be significantly related to risk of hematological relapse, giving patients with the higher mWBC the poorer outcome. The only other significant relapse-related risk factor was white-cell count at diagnosis. mWBC was not significantly related to white cell count at diagnosis, sex, age, or dose of methotrexate or mercaptopurine. Patients with low mWBC also had relatively low white-cell counts after cessation of therapy when compared with patients with high mWBC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3152971     DOI: 10.3109/08880018809037365

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  7 in total

1.  Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.

Authors:  K Schmiegelow; H Schrøder; M K Pulczynska; M Hejl
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

3.  6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.

Authors:  K Schmiegelow; I Bruunshuus
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council.

Authors:  G Dolan; J S Lilleyman; S M Richards
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

5.  Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters?

Authors:  K Schmiegelow; H Schrøder; M Schmiegelow
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.

Authors:  Anne McTiernan; Rachel C Jinks; Matthew R Sydes; Barbara Uscinska; Jane M Hook; Martine van Glabbeke; Vivien Bramwell; Ian J Lewis; Antonie H M Taminiau; Marianne A Nooij; Pancras C W Hogendoorn; Hans Gelderblom; Jeremy S Whelan
Journal:  Eur J Cancer       Date:  2011-10-27       Impact factor: 9.162

Review 7.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.